The Claim
In patients with homozygous familial hypercholesterolemia of Saudi Arabian origin who predominantly carry LDLR loss-of-function mutations, treatment with evolocumab 140 mg administered every two weeks is associated with a statistically significant reduction in low-density lipoprotein cholesterol levels, decreasing from a mean baseline of 10.15 mmol/L to 9.07 mmol/L, indicating a modest therapeutic effect in this genetically distinct population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people in Saudi Arabia with a rare genetic form of very high cholesterol, taking a drug called evolocumab every two weeks seems to lower their bad cholesterol a little bit — not a huge drop, but enough to show it's doing something.
See the scientific wording
In patients with homozygous familial hypercholesterolemia (HoFH) of Saudi Arabian origin carrying predominantly LDLR loss-of-function mutations, treatment with Evolocumab 140 mg every two weeks is associated with a statistically significant reduction in LDL-C levels from a mean of 10.15 mmol/L to 9.07 mmol/L, suggesting a modest therapeutic effect in this genetically distinct population.
What the research says
1 studyThe study looked at the same medicine, dose, and group of people mentioned in the claim, and found it did lower bad cholesterol significantly, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.